Dose Response of MARV/Angola Infection in Cynomolgus Macaques following IM or Aerosol Exposure

Marburg virus infection in humans causes a hemorrhagic disease with a high case fatality rate. Countermeasure development requires the use of well-characterized animal models that mimic human disease. To further characterize the cynomolgus macaque model of MARV/Angola, two independent dose response studies were performed using the intramuscular or aerosol routes of exposure. All animals succumbed at the lowest target dose; therefore, a dose effect could not be determined. For intramuscular-exposed animals, 100 PFU was the first target dose that was not significantly different than higher target doses in terms of time to disposition, clinical pathology, and histopathology. Although a significant difference was not observed between aerosol-exposed animals in the 10 PFU and 100 PFU target dose groups, 100 PFU was determined to be the lowest target dose that could be consistently obtained and accurately titrated in aerosol studies.

[1]  Joshua C. Johnson,et al.  Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques , 2015, Journal of Virology.

[2]  H. Feldmann,et al.  Ebola haemorrhagic fever , 2011, The Lancet.

[3]  M. Lackemeyer,et al.  Aerosol Exposure to the Angola Strain of Marburg Virus Causes Lethal Viral Hemorrhagic Fever in Cynomolgus Macaques , 2010, Veterinary pathology.

[4]  M. V. Van Kerkhove,et al.  Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment. , 2007, The Journal of infectious diseases.

[5]  P. Formenty,et al.  Marburg Virus Angola Infection of Rhesus Macaques: Pathogenesis and Treatment with Recombinant Nematode Anticoagulant Protein c2 , 2007, The Journal of infectious diseases.

[6]  A. Fauci.  Emerging and Reemerging Infectious Diseases: The Perpetual Challenge , 2005, Academic medicine : journal of the Association of American Medical Colleges.

[7]  B. Ligon,et al.  Outbreak of Marburg Hemorrhagic Fever in Angola: A Review of the History of the Disease and its Biological Aspects , 2005, Seminars in Pediatric Infectious Diseases.

[8]  M. Bray,et al.  Pathogenesis of filoviral haemorrhagic fevers. , 2004, The Lancet. Infectious diseases.

[9]  C. Roth,et al.  Risk Factors for Marburg Hemorrhagic Fever, Democratic Republic of the Congo , 2003, Emerging infectious diseases.

[10]  P. van der Stuyft,et al.  Short communication: A cluster of Marburg virus disease involving an infant * , 2002, Tropical medicine & international health : TM & IH.

[11]  M. Bray,et al.  Experimental therapy of filovirus infections. , 2002, Antiviral research.

[12]  D. Richman,et al.  Physicochemical properties of Marburg virus: evidence for three distinct virus strains and their relationship to Ebola virus. , 1988, The Journal of general virology.

[13]  K. Johnson,et al.  MARBURG-VIRUS DISEASE IN KENYA , 1982, The Lancet.

[14]  R. Salt,et al.  PERCUTANEOUS LUNG BIOPSY , 1976, The Lancet.

[15]  T. Bothwell,et al.  Outbreake of Marburg virus disease in Johannesburg. , 1975, British medical journal.

[16]  G. Martini,et al.  A hitherto unknown infectious disease contracted from monkeys. "Marburg-virus" disease. , 1968, German medical monthly.

[17]  S. Hazar,et al.  Filoviridae: Marburg and Ebola viruses. , 2000 .

[18]  R. Kurth,et al.  Characteristics of Filoviridae: Marburg and Ebola Viruses , 1999, Naturwissenschaften.

[19]  W. Slenczka.  The Marburg virus outbreak of 1967 and subsequent episodes. , 1999, Current topics in microbiology and immunology.

[20]  Slenczka Wg.  The Marburg virus outbreak of 1967 and subsequent episodes. , 1999 .

[21]  H. Feldmann,et al.  Marburg and Ebola viruses. , 1996, Advances in virus research.